Description
Piperacillin was synthesized by Toyama Chemicals Company in 1976by acylation of the amino residue of ampicillin. It shows excellent activity against a wide range of grampositive and gram-negative bacteria and has been used as the most potent semisynthetic penicillin. Piperacillin is administered intravenously or intramuscularly for therapy of sepsis, meningitis, respiratory and urinary tract infections, and for abdominal infections caused by Staphylococcus, Streptococcus, Escherichia coli, Klebsiella, Haemophilus influenzae, Serratia marcescens, Pseudomonas aeruginosa, Proteus, Enterobacter, Citrobacter, and Bacteroides.
